The activated FGF19-FGFR4 pathway enhances GSK3β-βcatenin signaling, consequently inducing EMT and resulting in increased HCC metastasis (165, 166) and CRC metastasis (47). The gene discussed is FGFR4; the disease is hepatocellular carcinoma.